Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.44 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779716 | 0.93 | KDR (0.46) | KDRTNNI3KMAP2K7HRH3RAF1 | |
| SCHEMBL2777014 | 0.81 | HRH3 (0.44) | KDRTNNI3KHRH3MAPK14BRAF | |
| SCHEMBL2435881 | 0.80 | AURKA (0.45) | KDRTNNI3KMAP2K7RAF1MAPK14 | |
| SCHEMBL2777158 | 0.74 | DRD2 (0.43) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL2777149 | 0.74 | HRH3 (0.41) | KDRTNNI3KHRH3MAPK14BRAF | |
| SCHEMBL10911483 | 0.72 | HRH3 (0.59) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL2776946 | 0.72 | HRH3 (0.44) | KDRHRH3CA12CA1CA2 | |
| SCHEMBL2780386 | 0.71 | KDR (0.49) | KDRTNNI3KMAP2K7RAF1MAPK14 | |
| SCHEMBL3183202 | 0.71 | HRH3 (0.48) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL2778534 | 0.70 | KDR (0.48) | KDRTNNI3KMAP2K7RAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885TNNI3K 270/4885MAP2K7 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.